For instance, one of the experimental drug candidates for the treatment of various types of cancer is obatoclax, which is a pan-inhibitor of the anti-apoptotic Bcl-2 protein (Konopleva et al., 2008; Yu et al., 2016). This evidence concerns the gene BCL2 and cancer.